Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Paul

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 30, 2025
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trialKathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
British Journal of Cancer|November 6, 2020
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2024
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized TrialsMarco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, et al.
BMC Cancer|March 20, 2026
PROTECTOR / FIRE‑10: study protocol for a prospective, randomized, open-label, multicenter phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancerRobert Siegel, Luca Dittrich, Julius Plewe, et al.
British Journal of Cancer|August 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trialsAlexej Ballhausen, Federica Morano, Arndt Stahler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2021
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)Dominik Paul Modest, Meinolf Karthaus, Stefan Fruehauf, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2025
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306Julian Walter Holch, Alexander J Ohnmacht, Sebastian Stintzing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2023
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) StudySebastian Stintzing, Kathrin Heinrich, David Tougeron, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2025
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancerLena Weiss, Sebastian Stintzing, Arndt Stahler, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|November 30, 2025
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trialKathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
British Journal of Cancer|November 6, 2020
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2024
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized TrialsMarco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, et al.
BMC Cancer|March 20, 2026
PROTECTOR / FIRE‑10: study protocol for a prospective, randomized, open-label, multicenter phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancerRobert Siegel, Luca Dittrich, Julius Plewe, et al.
British Journal of Cancer|August 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trialsAlexej Ballhausen, Federica Morano, Arndt Stahler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2021
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)Dominik Paul Modest, Meinolf Karthaus, Stefan Fruehauf, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2025
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306Julian Walter Holch, Alexander J Ohnmacht, Sebastian Stintzing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2023
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) StudySebastian Stintzing, Kathrin Heinrich, David Tougeron, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2025
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancerLena Weiss, Sebastian Stintzing, Arndt Stahler, et al.
Pageof 10